The overbought STI and SGX Next 50 stocks have captured the attention of investors as of 31 October 2025. Singapore’s two main indices provide a complementary view of the market: the STI highlights established blue-chip companies, while the Next 50 tracks mid-cap and growth-oriented firms. Together, they give a comprehensive picture of market sentiment and investor appetite.
How the SGX Next 50 Supports the STI
The SGX Next 50 acts as a growth engine for the STI, offering exposure to mid-cap companies poised for expansion. Rising momentum in these stocks often complements STI performance, and in late October 2025, several counters in both indices reached overbought conditions, reflecting strong investor confidence.
What “Overbought” Means in Market Terms
In technical analysis, a stock is considered overbought when it shows strong buying pressure, often measured with indicators like the RSI. While an overbought reading signals intense momentum, it does not necessarily indicate immediate downside risk. It simply suggests prices may have moved ahead of fundamentals and could consolidate.
Overbought STI Stocks as of 31 October 2025
Several blue-chip counters in the STI were technically overbought at month-end.
Wilmar International (SGX: F34)
Wilmar saw a strong rally fueled by commodity margin gains and regional growth. Its RSI exceeded the typical overbought threshold, reflecting heightened momentum.
Jardine Cycle & Carriage (SGX: C07)
Investor enthusiasm for automotive recovery lifted Jardine C&C shares into overbought territory. Its performance mirrors broader trends in the STI and Next 50.
Keppel Corporation (SGX: BN4)
Keppel’s strategic pivot toward renewable infrastructure and data centres drove its stock higher, placing it among the overbought STI and Next 50 stocks.
Mapletree Logistics Trust (SGX: M44U)
Strong rental performance and logistics sector growth contributed to Mapletree Logistics Trust entering overbought territory. Investors continue to value its income-generating profile.
Overbought SGX Next 50 Stocks as of 31 October 2025
Mid-cap growth names also experienced strong momentum during October 2025.
China Aviation Oil (SGX: G92)
CAO’s trading business benefited from regional aviation recovery, pushing it into the overbought category.
CSE Global (SGX: 544)
CSE Global’s engineering solutions for energy and infrastructure projects fueled investor interest, making it overbought.
First Resources (SGX: EB5)
Palm oil price stability and efficient operations led First Resources to strong technical momentum.
Riverstone Holdings (SGX: AP4)
Riverstone’s specialization in healthcare manufacturing and gloves production contributed to its overbought condition.
Sheng Siong Group (SGX: OV8)
Sheng Siong’s defensive retail performance and stable growth attracted buyers, pushing it into overbought territory.
Macro Factors Behind Overbought Conditions
Several factors contributed to the broad overbought readings in STI and Next 50 stocks:
- Regional economic recovery supporting multiple sectors.
- Neutral monetary policy, keeping borrowing costs stable.
- Foreign capital inflows seeking yield in Singapore equities.
- Investor rotation into mid-cap growth names alongside blue chips.
Balancing Momentum with Fundamentals
Although technical overbought signals indicate strong momentum, investors should also consider valuation metrics such as P/E ratios, dividends, and cash flow. Overbought stocks can remain strong for extended periods if fundamentals are solid.
Outlook and Considerations for Investors
Going into November 2025, investors should watch for:
- Earnings updates and Q4 guidance.
- Interest rate developments by the MAS.
- Rotation opportunities between overbought and undervalued sectors.
- Short-term consolidation in highly overbought counters.
Conclusion
The overbought STI and SGX Next 50 stocks of 31 October 2025 highlight a Singapore market with strong investor sentiment and liquidity. While technical momentum is impressive, careful portfolio management and attention to fundamentals remain essential for long-term investors.
Investment Disclaimer
This article is for informational purposes only and does not constitute financial advice. Investors should perform their own research or consult a licensed financial advisor before making investment decisions.